Oxytocin: Structure, Receptor and What the Research Shows

Key facts about oxytocin

• What it is: a peptide hormone of nine amino acids (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) in which a disulphide bond between the two cysteines closes a six-residue ring.
• Receptor: one G protein-coupled receptor, OXTR, found in the uterus, breast, ovary, brain, kidney, heart and other tissues.
• Medical use: a licensed medicine used by maternity teams during labour and after birth; WHO guidance recommends it to prevent heavy bleeding after childbirth.
• Behaviour research: early nasal spray findings on trust and social behaviour have mostly not held up in larger or preregistered studies.
• Stability: heat-sensitive and normally kept refrigerated; carbetocin, a longer-acting analogue, has a heat-stable formulation designed for hot climates.
• Identifiers: CAS 50-56-6; molecular formula C43H66N12O12S2; molecular weight 1007.2 g/mol (PubChem CID 439302).

Oxytocin was the first peptide hormone to be sequenced and synthesised, and it has long been a routine maternity medicine. In the 2000s it also became famous as the "love hormone", a label built largely on animal work and small human studies. This overview sets out what is established, what the behaviour research found once larger studies were run, and what is still unknown. The compound itself is profiled on our oxytocin page.

What is oxytocin?

Oxytocin is made by nerve cells in the paraventricular and supraoptic nuclei of the hypothalamus and released into the blood from the posterior pituitary gland; smaller amounts are made in the uterus, placenta and heart (Gimpl and Fahrenholz, 2001). Its name comes from the Greek for "quick birth": in 1906 Henry Dale, while studying ergot, noticed that pituitary extracts made the uterus contract (Dale, 1906).

The sequence is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly, with the final glycine capped as an amide. A disulphide bond between the cysteines at positions 1 and 6 closes a six-residue ring, leaving a three-residue tail. Vasopressin has the same layout and differs only at positions 3 and 8. Vincent du Vigneaud's group worked out the sequence in 1953 (du Vigneaud et al., 1953) and synthesised a peptide with the hormone's activity the same year (du Vigneaud et al., 1953). He received the 1955 Nobel Prize in Chemistry, cited above all for the first synthesis of a polypeptide hormone.

How does oxytocin work?

Oxytocin acts through one receptor, OXTR. The human receptor, cloned in 1992, is a 388-amino acid protein with seven membrane-spanning segments, typical of G protein-coupled receptors (Kimura et al., 1992). It signals mainly through Gq proteins to phospholipase C-beta, raising calcium inside the cell and, in smooth muscle, driving contraction (Gimpl and Fahrenholz, 2001). OXTR is found in:

• Uterus: receptor numbers in the muscle wall rise sharply just before labour, making it far more sensitive to oxytocin at term (Kimura et al., 1992).
• Breast: oxytocin drives milk let-down, and mice unable to make oxytocin cannot release milk (Gimpl and Fahrenholz, 2001).
• Brain: oxytocin neurons project widely, and in animals central oxytocin is linked to parental and social behaviour (Gimpl and Fahrenholz, 2001).
• Elsewhere: ovary, kidney, heart, thymus, pancreas and fat cells.

Steroid hormones strongly regulate the system, a feature the same review calls one of its least understood.

What is oxytocin used for in medicine?

Synthetic oxytocin is a licensed prescription medicine in the UK and many other countries. Maternity teams use it in hospital to start or strengthen contractions in labour and to help the uterus contract after birth, which limits bleeding. The WHO CHAMPION investigators describe postpartum haemorrhage as the most common cause of maternal death (Widmer et al., 2018), and WHO guidance recommends oxytocin to prevent it at all births (Vogel et al., 2019). Research-grade oxytocin sold for laboratory work is not a licensed medicine and is not for human use.

Why was oxytocin called the "love hormone"?

The social story began in prairie voles, one of the few mammals that form lasting pair bonds, where many pharmacological studies suggested that oxytocin receptor signalling was critical for partner preference (Berendzen et al., 2023). The human work took off in 2005, when a Nature study reported that volunteers given oxytocin by nasal spray entrusted more money to a stranger in an economic trust game than those given placebo (Kosfeld et al., 2005). Many nasal spray studies followed, reporting effects on a wide range of social judgements. Popular coverage condensed this into the "love hormone" label: a popular hypothesis, not a finding that held.

What happened to the intranasal oxytocin research?

• Trust did not replicate well. A 2015 critical review found that the trust finding had not replicated well, that blood oxytocin studies were flawed by how the hormone was measured, and that large genetic studies showed no consistent links with trust (Nave et al., 2015).
• The statistics were weak. Walum, Waldman and Young, in Biological Psychiatry, concluded that nasal oxytocin studies were generally underpowered and that most published findings probably did not represent true effects (Walum et al., 2016). Young's own prairie vole research helped build the field.
• Null results stayed in drawers. One Belgian laboratory reported that eight studies on 453 participants had yielded only five papers, just one reporting a null result, although the findings were too often not the expected ones (Lane et al., 2016).
• The flagship study failed a direct test. A large registered replication of the 2005 experiment, with more than 95% power and co-authored by Ernst Fehr, senior author of the original, found no effect of oxytocin on trust in the matching condition; an exploratory hint in low-trust people needs confirmation (Declerck et al., 2020).
• Measurement was unreliable. Commercial assays used on unprocessed samples lacked reliability and detected molecules other than oxytocin (McCullough et al., 2013), undermining many studies that correlate natural oxytocin levels with behaviour.

The clinical test came in autism. A 24-week placebo-controlled trial in 290 children and adolescents aged 3 to 17 found no significant difference between nasal oxytocin and placebo on social withdrawal, its main measure, and secondary social and cognitive measures generally did not differ either. The authors noted that oxytocin was already used in clinical practice for many autistic children (Sikich et al., 2021). None of this shows that oxytocin has no part in human social behaviour, only that the striking early effects mostly did not survive larger tests.

Does oxytocin reach the brain?

Nasal sprays assume that some peptide travels directly from the nose to the brain (Quintana et al., 2021). Whether enough does to matter is still argued over.

• The sceptical case. Very little of the large amount sprayed appears to reach the cerebrospinal fluid, while blood levels rise far above normal, with likely effects on the gut, heart and reproductive tract, so behavioural effects could come from the body rather than the brain (Leng and Ludwig, 2016).
• Human spinal fluid. In 15 volunteers (11 given oxytocin), levels rose in blood and cerebrospinal fluid, but the fluid took up to 75 minutes to change and did not correlate with blood (Striepens et al., 2013). The study was small, and its assay could not separate sprayed oxytocin from the body's own.
• Labelled oxytocin in monkeys. In rhesus macaques, deuterium-labelled oxytocin reached the cerebrospinal fluid by nasal and intravenous routes alike (Lee et al., 2018). A follow-up found it in brain tissue, including the striatum and orbitofrontal cortex, after nasal but not intravenous delivery, along olfactory and trigeminal nerve pathways (Lee et al., 2020).

Quintana and colleagues argue the evidence now converges on functionally relevant nose-to-brain delivery. The fair summary is narrower: some nasally delivered oxytocin can reach the primate brain, but how much reaches which human brain regions, and whether that changes behaviour, is unsettled.

How stable is oxytocin, and what is carbetocin?

Oxytocin breaks down with heat. In accelerated studies at 40 to 80°C, degradation depended on temperature and pH and produced deamidated forms, altered disulphide bridges and clumped aggregates (Hawe et al., 2009). Medical oxytocin therefore normally needs refrigeration, which many health systems struggle to maintain. A WHO-linked review of 559 samples from 15 low- and middle-income countries found a median of 45.6% failed quality tests, mostly from too little active ingredient (Torloni et al., 2016).

Carbetocin is a long-acting synthetic oxytocin agonist (Su et al., 2012). Ferring Pharmaceuticals developed a heat-stable formulation, taken forward with WHO for lower-income countries, that kept at least 95% purity for 3 years at 30°C (Malm et al., 2018). The WHO CHAMPION trial randomised 29,645 women in 10 countries to it or oxytocin after vaginal birth. Carbetocin was non-inferior for blood loss of at least 500 ml or need for extra uterotonics (14.5% versus 14.4%), but non-inferiority was not shown for blood loss of at least 1,000 ml, where low event rates reduced power. Both drugs were refrigerated during the trial to preserve blinding (Widmer et al., 2018). WHO recommends carbetocin where its cost is comparable to other effective options (Vogel et al., 2019).

The same chemistry is why lyophilised research peptides such as oxytocin are generally stored cold and dry; our guide to bacteriostatic water for peptides covers laboratory handling more broadly.

What is not known?

• Brain delivery in people: how much nasally delivered oxytocin reaches human brain tissue, and how much of any effect comes from the body instead.
• Which behavioural effects are real: few large, preregistered studies show a reliable effect on any specific human social behaviour.
• What natural oxytocin does: prairie voles bred without a working oxytocin receptor still formed partner preferences, gave birth and raised pups (Berendzen et al., 2023), so its role in human relationships is an open question.
• Measurement: without an accurate, widely adopted assay, links between natural oxytocin levels and behaviour remain hard to interpret.
• Long-term effects outside obstetrics: trials have mostly run for weeks or months, and oxytocin is not licensed for any psychiatric or behavioural condition.

The bottom line

Oxytocin is a well-characterised hormone with a narrow, established medical role around childbirth. The leap to a "love hormone" in a nasal spray outran the evidence: the headline trust finding failed a large replication, the field's statistics were weak, a large autism trial was negative, and brain delivery is still debated. Claims about oxytocin and behaviour deserve the scrutiny the field has since applied to itself.

References

1. Berendzen KM, et al. (2023). Oxytocin receptor is not required for social attachment in prairie voles. Neuron. PubMed 36708707
2. Dale HH. (1906). On some physiological actions of ergot. The Journal of Physiology. PubMed 16992821
3. Declerck CH, et al. (2020). A registered replication study on oxytocin and trust. Nature Human Behaviour. PubMed 32514040
4. du Vigneaud V, et al. (1953). The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. Journal of Biological Chemistry. PubMed 13129273
5. du Vigneaud V, et al. (1953). The synthesis of an octapeptide amide with the hormonal activity of oxytocin. Journal of the American Chemical Society. doi:10.1021/ja01115a553
6. Gimpl G, et al. (2001). The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. PubMed 11274341
7. Hawe A, et al. (2009). Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharmaceutical Research. PubMed 19343484
8. Kimura T, et al. (1992). Structure and expression of a human oxytocin receptor. Nature. PubMed 1313946
9. Kosfeld M, et al. (2005). Oxytocin increases trust in humans. Nature. PubMed 15931222
10. Lane A, et al. (2016). Is there a Publication Bias in Behavioural Intranasal Oxytocin Research on Humans? Opening the File Drawer of One Laboratory. Journal of Neuroendocrinology. PubMed 26991328
11. Lee MR, et al. (2018). Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Molecular Psychiatry. PubMed 28289281
12. Lee MR, et al. (2020). Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nature Communications. PubMed 32494001
13. Leng G, et al. (2016). Intranasal Oxytocin: Myths and Delusions. Biological Psychiatry. PubMed 26049207
14. Malm M, et al. (2018). Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science. PubMed 29700898
15. McCullough ME, et al. (2013). Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neuroscience and Biobehavioral Reviews. PubMed 23665533
16. Nave G, et al. (2015). Does Oxytocin Increase Trust in Humans? A Critical Review of Research. Perspectives on Psychological Science. PubMed 26581735
17. Quintana DS, et al. (2021). Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Molecular Psychiatry. PubMed 32807845
18. Sikich L, et al. (2021). Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine. PubMed 34644471
19. Striepens N, et al. (2013). Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Scientific Reports. PubMed 24310737
20. Su LL, et al. (2012). Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews. PubMed 22513931
21. Torloni MR, et al. (2016). Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. PubMed 27006180
22. Vogel JP, et al. (2019). WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ Global Health. PubMed 31139461
23. Walum H, et al. (2016). Statistical and Methodological Considerations for the Interpretation of Intranasal Oxytocin Studies. Biological Psychiatry. PubMed 26210057
24. Widmer M, et al. (2018). Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. New England Journal of Medicine. PubMed 29949473